Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
University of Heidelberg Medical Center
Pfizer
National Institutes of Health Clinical Center (CC)
Juno Therapeutics, a Subsidiary of Celgene
Astex Pharmaceuticals, Inc.
Amgen
Nordic Nanovector
Sunnybrook Health Sciences Centre
Children's Oncology Group
Takeda
Northwestern University
AbbVie
Baylor College of Medicine
Merck Sharp & Dohme LLC
Takeda
Jonsson Comprehensive Cancer Center
Amgen Research (Munich) GmbH
Baylor College of Medicine
Baylor College of Medicine
LEO Pharma
National Institutes of Health Clinical Center (CC)
New York Medical College
Alliance for Clinical Trials in Oncology
Amgen Research (Munich) GmbH
National Institutes of Health Clinical Center (CC)
Wake Forest University Health Sciences
Vanderbilt University Medical Center
Amgen Research (Munich) GmbH
Mayo Clinic
Alliance for Clinical Trials in Oncology
Amgen Research (Munich) GmbH
Amgen Research (Munich) GmbH
Radiation Therapy Oncology Group
Alliance for Clinical Trials in Oncology
Novartis
FDA Office of Orphan Products Development
Seagen Inc.
Seagen Inc.
Seagen Inc.
Seagen Inc.
Seagen Inc.
Children's Oncology Group
AVEO Pharmaceuticals, Inc.
Vifor Pharma
Asan Medical Center
Vanderbilt-Ingram Cancer Center
National Institutes of Health Clinical Center (CC)
Cancer Research UK
Case Comprehensive Cancer Center
Mayo Clinic